Dexcom (DXCM) Other Accumulated Expenses (2011 - 2026)

Dexcom (DXCM) has 16 years of Other Accumulated Expenses data on file, last reported at $7.6 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $7.6 million, down 84.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 million (down 84.89% YoY), and the FY2025 annual result was $7.7 million, down 79.25% from the prior year.
• Other Accumulated Expenses eased to $7.6 million in Q1 2026 per DXCM's latest filing, from $7.7 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $62.9 million in Q1 2022 and troughed at $7.6 million in Q1 2026.
• A 5-year average of $40.5 million and a median of $42.0 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses jumped 41.67% in 2022, then sank 84.89% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $39.7 million in 2022, then grew by 2.02% to $40.5 million in 2023, then dropped by 8.4% to $37.1 million in 2024, then plunged by 79.25% to $7.7 million in 2025, then dropped by 1.3% to $7.6 million in 2026.
• Business Quant data shows DXCM's Other Accumulated Expenses at $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $42.0 million in Q3 2025.